Therapeutic Approach

Archive: February, 2012

Ritter Pharmaceuticals’ Abstract on RP-G28’s Phase 2 Trial Selected for Oral Presentation at Digestive Disease Week 2012

LOS ANGELES, CA – February 15, 2012– Ritter Pharmaceuticals, Inc. has announced today that the abstract summarizing results from its Phase 2 study of RP-G28, a first-in-class treatment for lactose intolerance, was chosen for oral presentation at the annual international Digestive Disease Week (DDW) 2012®, considered the largest meeting in the world for physicians and […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD